首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1370922

腎癌藥物市場-2018-2028年全球產業規模、佔有率、趨勢、機會與預測，依治療類別、藥理學類別（血管新生抑制劑、單株抗體、mTOR抑制劑）、地區、競爭細分

Kidney Cancer Drugs Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2018-2028 Segmented By Therapeutic Class, Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors), Region, Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022年全球腎癌藥物市場估值達62.8億美元，預計在預測期內將出現大幅成長，預計年複合成長率（CAGR）為6.50%，預計到2022年將達到91.8億美元2028. 腎癌，醫學上稱為腎細胞癌(RCC)，是一種起源於腎臟的複雜疾病，腎臟是負責過濾血液中廢物和多餘液體以產生尿液的重要器官。腎癌的治療是一項具有挑戰性的任務，需要有效的策略。隨著醫學研究的進步和藥物創新的加速，腎癌藥物市場的成長和演變受到幾個關鍵促進因素的推動。

主要市場促進因素：

1.研究和開發的進步：製藥公司、學術機構和研究組織正在投入大量資源，以深入了解腎癌的基礎生物學。這項投資確定了導致腎癌發生和進展的關鍵分子途徑、基因突變和生物標記。這些進步為標靶治療的發展奠定了基礎，標靶治療的重點是抑制與癌症生長有關的特定分子或途徑。例子包括酪胺酸激酶抑制劑 (TKI) 和 mTOR 抑制劑，它們透過提供更有效和毒性更低的療法而改變了腎癌的治療。

市場概況
預測期	2024-2028
2022 年市場規模	62.8億美元
2028 年市場規模	91.8億美元
2023-2028 年年複合成長率	6.50%
成長最快的細分市場	標靶治療
最大的市場	北美洲

2.免疫療法革命：免疫療法的出現為包括腎臟癌在內的多種癌症的治療帶來了革命。免疫檢查點抑制劑，例如PD-1和PD-L1抑制劑，透過利用人體的免疫系統來識別和攻擊癌細胞，顯示出了顯著的功效。這些療法不僅延長了生存率，也為創新的聯合療法鋪平了道路。研究人員正在積極探索如何將標靶療法與免疫療法協同發揮作用，以實現更強勁的反應。免疫療法的出現開創了癌症治療的新時代。
3.不斷湧現的臨床試驗創新：臨床試驗是評估腎癌新藥安全性和有效性的基礎。創新的試驗設計，結合生物標記驅動的終點和適應性試驗設計，正在推動藥物開發向前發展。生物標記驅動的試驗能夠選擇最有可能對特定治療產生反應的患者，而適應性試驗設計允許根據累積的資料進行即時修改，從而提高試驗效率和決策。

主要市場挑戰：

1.抗藥性和治療異質性：儘管標靶治療和免疫療法取得了進展，但對這些治療的抗藥性的發展仍然是腎癌的重大挑戰。腫瘤會隨著時間的推移而適應，使曾經有效的療法變得無效。這突顯出需要持續研究以了解抗藥性機制並制定克服抗藥性的策略。此外，腎癌不是一種同質性疾病，不同的亞型和基因變異導致治療反應的改變。開發對不同患者群體有效的療法是一項複雜的工作。
2.缺乏預測性生物標記：缺乏可靠的預測性生物標記阻礙了有效腎癌藥物的開發。能夠準確識別可能對特定治療產生反應的患者的生物標記對於個人化醫療方法至關重要。目前，沒有任何一種生物標記能夠對所有患者和治療方式表現出一致的預測價值。缺乏可靠的生物標記使得醫療保健專業人員很難做出明智的治療決策。
3.免疫相關不良事件 (irAE)：免疫療法雖然在癌症治療中具有變革性，但由於會激活免疫系統，因此可能導致免疫相關不良事件 (irAE)。這些事件可能會影響多個器官，因此需要仔細管理以平衡免疫活化與潛在危害。 irAE 的發生和嚴重程度會影響患者的依從性、生活品質和整體治療成功。

主要市場趨勢：

1.個人化醫療革命：個人化醫療的出現為改善腎癌治療的患者預後提供了廣闊的前景。精準腫瘤學根據個別基因圖譜和生物標記表達客製化干涉措施，擺脫一刀切的方法。基因組學和分子診斷的進步使腫瘤學家能夠識別導致患者腎癌的特定基因突變或變化。這些資訊可以指導標靶治療的處方，提高成功的可能性，提高藥物療效並最大限度地減少不良反應。
2.聯合療法：同時或相繼合併多種治療正成為增強腎癌治療效果和克服抗藥性的強大策略。透過將標靶療法與免疫療法或其他治療方式相結合而實現的協同作用提供了攻擊癌細胞的多方面方法。對能夠最大限度提高治療效果的新型組合的探索正在推動對腎癌藥物的需求。實現更好的反應和延長疾病控制的潛力正在激發合作努力，以確定不同治療方法之間的最佳協同作用。

細分洞見：

治療類別洞察： 2022年，免疫治療領域主導腎癌藥物市場，佔最大佔有率。人們對創新免疫療法和免疫腫瘤藥物的日益青睞正在推動標靶療法的使用，特別是在特定患者亞群中或作為後期治療，這增加了需求。

區域見解：北美已成為全球腎癌藥物市場的領導者。這可以歸因於廣泛的醫療支出和有利的治療報銷規定。此外，人口中吸菸、高血壓和糖尿病的高盛行率，以及主要製藥商的存在，使得亞太地區在預測期內腎癌藥物市場將經歷最高的成長。

The Global Kidney Cancer Drugs Market achieved a valuation of USD 6.28 Billion in 2022, and it is expected to experience substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.50% and is expected to reach USD 9.18 Billion by 2028. Kidney cancer, medically known as renal cell carcinoma (RCC), is a complex disease originating in the kidneys, vital organs responsible for filtering waste and excess fluids from the blood to produce urine. The treatment of kidney cancer is a challenging task, demanding effective strategies. The growth and evolution of the kidney cancer drugs market are being propelled by several key drivers as medical research advances and pharmaceutical innovation accelerates.

Key Market Drivers:

1. Advancements in Research and Development: Significant resources are being invested by pharmaceutical companies, academic institutions, and research organizations to gain a deep understanding of the underlying biology of kidney cancer. This investment has led to the identification of crucial molecular pathways, genetic mutations, and biomarkers responsible for driving the development and progression of kidney cancer. These advancements have laid the foundation for the development of targeted therapies, which focus on inhibiting specific molecules or pathways involved in cancer growth. Examples include tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, which have transformed kidney cancer treatment by providing more effective and less toxic therapies.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 6.28 Billion
Market Size 2028	USD 9.18 Billion
CAGR 2023-2028	6.50%
Fastest Growing Segment	Targeted Therpay
Largest Market	North America

2. Immunotherapy Revolution: The advent of immunotherapies has brought about a revolution in the treatment of various cancers, including kidney cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy by harnessing the body's immune system to recognize and attack cancer cells. These therapies have not only extended survival rates but have also paved the way for innovative combination therapies. Researchers are actively exploring how to synergize targeted therapies with immunotherapies to achieve even more robust responses. The emergence of immunotherapies has ushered in a new era of cancer treatment.

3. Rising Clinical Trial Innovation: Clinical trials are fundamental in evaluating the safety and efficacy of new kidney cancer drugs. Innovative trial designs, incorporating biomarker-driven endpoints and adaptive trial designs, are propelling drug development forward. Biomarker-driven trials enable the selection of patients most likely to respond to a particular therapy, while adaptive trial designs allow real-time modifications based on accumulating data, enhancing trial efficiency and decision-making.

Key Market Challenges:

1. Resistance and Treatment Heterogeneity: Despite the progress made in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Tumors can adapt over time, rendering once-effective therapies ineffective. This highlights the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Moreover, kidney cancer is not a homogeneous disease, with different subtypes and genetic variations contributing to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor.

2. Lack of Predictive Biomarkers: The absence of reliable predictive biomarkers hinders the development of effective kidney cancer drugs. Biomarkers that can accurately identify patients likely to respond to a particular treatment are essential for personalized medicine approaches. Currently, no single biomarker has demonstrated consistent predictive value across all patients and treatment modalities. The lack of reliable biomarkers makes it challenging for healthcare professionals to make informed treatment decisions.

3. Immune-Related Adverse Events (irAEs): Immunotherapies, while transformative in cancer treatment, can lead to immune-related adverse events (irAEs) as they activate the immune system. These events can affect various organs, necessitating careful management to balance immune activation against potential harm. The occurrence and severity of irAEs can impact patient compliance, quality of life, and overall treatment success.

Key Market Trends:

1. Personalized Medicine Revolution: The advent of personalized medicine is offering promising prospects for improved patient outcomes in kidney cancer treatment. Precision oncology tailors interventions based on individual genetic profiles and biomarker expression, moving away from a one-size-fits-all approach. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. This information guides the prescription of targeted therapies with a higher likelihood of success, enhancing drug efficacy and minimizing adverse effects.

2. Combination Therapies: Combining multiple treatments simultaneously or sequentially is emerging as a powerful strategy to enhance treatment efficacy and overcome resistance in kidney cancer. The synergy achieved by combining targeted therapies with immunotherapies or other treatment modalities offers a multifaceted approach to attacking cancer cells. The exploration of novel combinations that maximize treatment outcomes is driving the demand for kidney cancer drugs. The potential to achieve better responses and prolonged disease control is spurring collaborative efforts to identify the optimal synergy between different therapeutic approaches.

Segmental Insights:

Therapeutic Class Insights: In 2022, the immunotherapy segment dominated the Kidney Cancer Drugs Market, holding the largest share. The increasing preference for innovative immunotherapies and immune-oncologic drugs is driving the use of targeted therapies, particularly in specific patient subpopulations or as later lines of treatment, which is boosting demand.

Regional Insights: North America has established itself as the leader in the Global Kidney Cancer Drugs Market. This can be attributed to widespread healthcare spending and favorable reimbursement regulations for therapy. Furthermore, the high prevalence of smoking, hypertension, and diabetes among its population, along with the presence of major pharmaceutical manufacturers, positions Asia-Pacific to experience the highest growth in the kidney cancer drugs market during the forecast period.

Key Market Players

Novartis AG
Pfizer Inc.
Bayer AG
Genentech Inc.
Bristol-Myers Squibb
Eisai Co., Ltd.
Exelixis Inc
Prometheus Laboratories Inc
Glaxosmithkline PLC.
F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Kidney Cancer Drugs Market, By Therapeutic Class:

Targeted Therapy
Immunotherapy
Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)

Global Kidney Cancer Drugs Market, By Region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
- 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
- 5.2.3. By Company (2022)
- 5.2.4. By Region
5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapeutic Class
- 6.2.2. By Pharmacologic Class
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Kidney Cancer Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapeutic Class
    - 6.3.1.2.2. By Pharmacologic Class
- 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapeutic Class
    - 6.3.2.2.2. By Pharmacologic Class
- 6.3.3. Canada Kidney Cancer Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapeutic Class
    - 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value & Volume
7.2. Market Share & Forecast
- 7.2.1. By Therapeutic Class
- 7.2.2. By Pharmacologic Class
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Kidney Cancer Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapeutic Class
    - 7.3.1.2.2. By Pharmacologic Class
- 7.3.2. Germany Kidney Cancer Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapeutic Class
    - 7.3.2.2.2. By Pharmacologic Class
- 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapeutic Class
    - 7.3.3.2.2. By Pharmacologic Class
- 7.3.4. Italy Kidney Cancer Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapeutic Class
    - 7.3.4.2.2. By Pharmacologic Class
- 7.3.5. Spain Kidney Cancer Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapeutic Class
    - 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value & Volume
8.2. Market Share & Forecast
- 8.2.1. By Therapeutic Class
- 8.2.2. By Pharmacologic Class
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Kidney Cancer Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapeutic Class
    - 8.3.1.2.2. By Pharmacologic Class
- 8.3.2. India Kidney Cancer Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapeutic Class
    - 8.3.2.2.2. By Pharmacologic Class
- 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapeutic Class
    - 8.3.3.2.2. By Pharmacologic Class
- 8.3.4. Japan Kidney Cancer Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapeutic Class
    - 8.3.4.2.2. By Pharmacologic Class
- 8.3.5. Australia Kidney Cancer Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapeutic Class
    - 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapeutic Class
- 9.2.2. By Pharmacologic Class
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapeutic Class
    - 9.3.1.2.2. By Pharmacologic Class
- 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapeutic Class
    - 9.3.2.2.2. By Pharmacologic Class
- 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapeutic Class
    - 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapeutic Class
- 10.2.2. By Pharmacologic Class
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapeutic Class
    - 10.3.1.2.2. By Pharmacologic Class
- 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapeutic Class
    - 10.3.2.2.2. By Pharmacologic Class
- 10.3.3. UAE Kidney Cancer Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapeutic Class
    - 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
- 15.6.1. Novartis AG
- 15.6.2. Pfizer Inc.
- 15.6.3. Bayer AG
- 15.6.4. Genentech Inc.
- 15.6.5. Bristol-Myers Squibb
- 15.6.6. Eisai Co., Ltd.
- 15.6.7. Exelixis Inc
- 15.6.8. Prometheus Laboratories Inc
- 15.6.9. GlaxoSmithKline Plc
- 15.6.10. F. Hoffmann-LA Roche AG